First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

PURPOSE: This first-in-human, dose-escalation and dose-expansion study evaluated the safety, tolerability, and antitumor activity of datopotamab deruxtecan (Dato-DXd), a novel trophoblast cell-surface antigen 2 (TROP2)–directed antibody-drug conjugate in solid tumors, including advanced non–small-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Toshio, Sands, Jacob, Yoh, Kiyotaka, Spira, Alexander, Garon, Edward B., Kitazono, Satoru, Johnson, Melissa L., Meric-Bernstam, Funda, Tolcher, Anthony W., Yamamoto, Noboru, Greenberg, Jon, Kawasaki, Yui, Zebger-Gong, Hong, Kobayashi, Fumiaki, Phillips, Penny, Lisberg, Aaron E., Heist, Rebecca S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564307/
https://www.ncbi.nlm.nih.gov/pubmed/37327461
http://dx.doi.org/10.1200/JCO.23.00059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564307/
https://www.ncbi.nlm.nih.gov/pubmed/37327461
http://dx.doi.org/10.1200/JCO.23.00059

Ejemplares similares